WHO-Recommended Periodic Presumptive Treatment versus Doxycycline Post-Exposure Prophylaxis for STI Control among Cisgender Men Who Have Sex with Men in Kenya
- Conditions
- bacterial sexually transmitted infections including gonorrhea, chlamydia, and syphilis
- Registration Number
- PACTR202407778358273
- Lead Sponsor
- ational Institute of Allergy and Infectious Diseases
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Pending
- Sex
- Male
- Target Recruitment
- 2900
• 18-29 years old
• Assigned male sex at birth
• Identifies as male (cis-gender)
• Reports condomless anal intercourse with a man in the past 6 months
• Reports multiple male sex partners OR a male sex partner with a syndromic (urethritis, proctitis, or genital ulcer disease) or laboratory-diagnosed sexually transmitted infection in the past 6 months
• Willing and able to provide written informed consent and participate in all study procedures
• Planning to remain in the study area for 18 months
• Unable to understand the study purpose and procedures
• Allergy to cephalosporin (cefixime), macrolide (erythromycin or azithromycin), or tetracycline (doxycycline) class antibiotics
• Recent use of prolonged antibiotics (=14-day course in the month before enrolment)
• Use of medications that impact cefixime, azithromycin, or doxycycline metabolism (check versus list in screening SOP)
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method